VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma

Title
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma
Author(s)
김민경현명수배영경이경희서철원[서철원]지현숙[지현숙]이경원[이경원]김인숙[김인숙]엄현석[엄현석]공선영[공선영]배성화[배성화]류헌모[류헌모]신임희[신임희]문영철[문영철]정화순[정화순]조희순
Keywords
ENDOTHELIAL GROWTH-FACTOR; CHEMOTHERAPY PLUS RITUXIMAB; NON-HODGKINS-LYMPHOMA; LUNG-CANCER; R-CHOP; MICROVESSEL DENSITY; CLINICAL-RELEVANCE; COLORECTAL-CANCER; EXPRESSION; RECEPTORS
Issue Date
201203
Publisher
WILEY-BLACKWELL
Citation
CANCER SCIENCE, v.103, no.3, pp.497 - 503
Abstract
We evaluated the impact of functional polymorphisms in the vascular endothelial growth factor A (VEGFA) and vascular endothelial growth factor 2 (VEGFR2) genes on the survival of patients with diffuse large B cell lymphoma (DLBCL). Five potentially functional polymorphisms in the VEGFA (rs699947, rs2010963 and rs3025039) and VEGFR2 (rs1870377 and rs2305948) genes were assessed in 494 DLBCL patients treated with rituximab plus CHOP chemotherapy. The associations of genotype and haplotype with overall survival (OS) and progression-free survival (PFS) were analyzed. Of the five polymorphisms, VEGFR2 rs1870377T>A was significantly associated with both OS and PFS; in the dominant model, patients with the AA + TA genotypes had significantly better OS (P = 0.002) and PFS (P = 0.004) than those with the TT genotype. The association between significantly better OS and the AA + TA genotypes was observed separately in patients with low (02; P = 0.035) and high (35; P = 0.043) International Prognostic Index scores. Multivariate analysis showed that, relative to the AA + TA genotypes, the TT genotype was an independent prognostic factor for poor OS (HR, 1.71; 95% CI, 1.212.43; P = 0.002) and PFS (HR, 1.57; 1.132.17; P = 0.004). Other independent significant predictors of survival in patients with DLBCL were International Prognostic Index score, age > 60 years, lactate dehydrogenase concentration >normal, extranodal disease >1 and presence of B symptoms. The VEGFR2 rs1870377 polymorphism might affect survival in patients with DLBCL, suggesting that angiogenesis might be related to poor survival in these patients. (Cancer Sci 2012; 103: 497503)
URI
http://hdl.handle.net/YU.REPOSITORY/29640http://dx.doi.org/10.1111/j.1349-7006.2011.02168.x
ISSN
1347-9032
Appears in Collections:
의과대학 > 내과학교실 > Articles
의과대학 > 병리학교실 > Articles
의과대학 > 진단검사의학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE